tag ash 
pharmaphorum
DECEMBER 12, 2022
Dutch biotech Argenx is on course to add another rare disease indication to the label of its FcRn blocker Vyvgart – primary immune thrombocytopenia (ITP) – thanks to new data reported at the ASH annual meeting. The post ASH: Argenx cues up a second use for efgartigimod appeared first on.
World of DTC Marketing
SEPTEMBER 7, 2022
In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. ASH Clinical News takes it a step further. Wall Street wants growth, as do investors, but that may be impossible for pharmaceutical companies.
pharmaphorum
DECEMBER 23, 2022
price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Oral therapy data presented at ASH. CellCentric, a U.K-based
Expert insights. Personalized for you.
52 
Let's personalize your content